Logo-bi
Review
Sanjay Singh*
Bioimpacts. 2013;3(2): 53-65. doi: 10.5681/bi.2013.007
PMCID: PMC3713871     PMID: 23878788     Scopus ID: 84881502609    
PDF
XML
Cited By:
Editorial
Miguel de la Guardia*
Bioimpacts. 2014;4(1): 1-2. doi: 10.5681/bi.2014.009
PMCID: PMC4005277     PMID: 24790892     Scopus ID: 84900478943    
PDF
XML
Cited By:
Editorial
Javad Shokri*
Bioimpacts. 2017;7(4): 207-208. doi: 10.15171/bi.2017.24
PMCID: PMC5801531     PMID: 29435427     Scopus ID: 85040988305    
Review
Clarence S Yah* ORCID, Geoffrey S. Simate
Bioimpacts. 2020;10(3): 195-203. doi: 10.34172/bi.2020.24
PMCID: PMC7416007     PMID: 32793442     Scopus ID: 85089711934    
The impact of bio-nanomaterials XCELLigence-cytotoxicity testing. A non-invasive in-vitro monitoring process that mimics exact continuous cellular bio-responses. However, to expand and affirm consumer safety concerns of bio-nanomaterials, additional XCELLigence data is required for bio-nanomaterials toxicity protocols and methodological development.
Editorial
Marziyeh Fathi ORCID, Azam Safary ORCID, Jaleh Barar* ORCID
Bioimpacts. 2020;10(1): 1-4. doi: 10.15171/bi.2020.01
PMCID: PMC6977590     PMID: 31988850     Scopus ID: 85078980716    
Jaleh Barar (PharmD, PhD) is Professor of Drug Delivery and Targeting. She currently is the chair of the department of Pharmaceutics at the Faculty of Pharmacy, Tabriz university of Medical Sciences. Professor Barar’s research is focused on various aspects of the pharmaceutical cell biology with the particular emphasis on the development of novel drug delivery and targeting strategies to combat cancer.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge